QIAcube Wins Red Dot Design Award
QIAGEN's new processing platform honored with one of the world's most prestigious design awards
VENLO, The Netherlands, March 19, 2007 - QIAGEN N.V., a worldwide leading provider of sample and assay technologies, today announced that its most recently launched instrument, the QIAcube, has received the Red Dot Award, one of the most prestigious competitions of the design industry.
The Red Dot award is awarded annually and winners are selected from all industries. The QIAcube is one of the very few products in life sciences or diagnostics to have won this award.
The international expert jury honored the exceptional features of the QIACube in categories such as innovation, functionality, formal quality and ergonomics. The Red Dot Award is already the second international award which the QIAcube has received. In January, the QIAcube was awarded the New Product Award of the Association for Laboratory Automation (ALA) at the LabAutomation in Palm Springs, Ca., the world's largest conference on and exhibition of laboratory technologies. QIAcube was introduced to the public for the first time at LabAutomation in January 2007.
"We are very proud to have received the so prestigious Red Dot Award which recognizes the inspirational, functional and ergonomical features of QIAcube", said Wolfgang Leibinger, Global Business Director, Automated Systems for QIAGEN. "Significant efforts and focus were invested on these features with the intent to allow a level of ease of use and functionality new to our industry. QIAcube has achieved a tremendous response from customers and been awarded for its novel technological capabilities. We are very pleased by the recognition of the design and technological capabilities of QIAcube."
The Red Dot Award will be presented to QIAGEN on June 25 in Germany, witnessed by over 1.000 guests. Together with other products the platform will then be displayed in a special exhibition and subsequently shown for one year in the Red Dot Museum, the world's largest exhibition for contemporary design.
QIAcube is a compact platform incorporating novel and proprietary technologies that allows users to fully automate the processing of almost all QIAGEN consumable products that today are used manually in over 40,000 biological laboratories throughout the world. The versatile, compact system in the low throughput range creates a new level of utility and opportunities to free up time, reduce costs, and increase performance for customers in any laboratory conducting molecular biology research in life science, applied testing and molecular diagnostics. The platform is priced at a fraction of current instrumentation products and was launched for use with up to 100 protocols which address almost any need in sample processing. The protocols are based on the identical QIAGEN consumable products used manually today - enabling fast and effortless migration of existing QIAGEN consumable users to the QIAcube.
- Customers: Worldwide over 40,000 laboratories conducting molecular biology research in life science, applied testing and molecular diagnostics
- Applications: Low throughput (up to 12 samples per run) >100 spin-column based protocols for DNA, RNA, protein sample processing
- Developed by QIAGEN: includes proprietary technologies
- Size / weight: 65 cm (25.5 in) X 57 cm (22.4 in) X 62 cm (24.4 in) / 70.5 kg (155 lbs)
- QIAcube is intended for research use only. No claim of representation is intended for its use to provide information for the diagnosis, prevention or treatment of a disease.
- More information on the QIAcube, images and video materials are available at
About Red Dot Design Award:
The red dot award is one of the largest and most renowned design competitions worldwide. It is divided into the "red dot award: product design", the "red dot award: communication design" and the "red dot award: design concept." This year, companies from 43 countries submitted applications for 2,548 products. More information on http://www.red-dot.de/
QIAGEN N.V., a Netherlands holding company, is the worldwide leading provider of sample and assay technologies for research in life sciences, applied testing and molecular diagnostics. The products are considered standards in areas such as pre-analytical sample preparation and molecular diagnostics solutions. QIAGEN has developed a comprehensive portfolio of more than 500 proprietary, consumable products and automated solutions for sample collection, nucleic acid and protein handling, separation, and purification and open and target specific assays. The company's products are sold to academic research markets, to leading pharmaceutical and biotechnology companies, to applied testing customers (such as in forensics, veterinary, bio-defense and industrial applications) as well as to molecular diagnostics laboratories. QIAGEN employs more than 1,950 people worldwide. QIAGEN products are sold through a dedicated sales force and a global network of distributors in more than 40 countries. Further information about QIAGEN can be found at http://www.qiagen.com/.
Dr. Thomas Theuringer